IPOs

Rare disease biotech Inozyme Pharma prices further upsized IPO at $16, in line with upwardly revised terms

Inozyme Pharma, a preclinical biotech developing protein therapies for rare calcification diseases, raised $112 million by offering 7 million shares at $16, in line with the upwardly revised terms. The company offered 0.5 million more shares than anticipated. It originally filed to offer 5 million shares at a range of $14 to $16, before increasing its proposed deal size on Thursday morning. At pricing, the company commands a fully diluted market cap of $386 million.

Inozyme Pharma plans to list on the Nasdaq under the symbol INZY. BofA Securities, Cowen, and Piper Sandler acted as lead managers on the deal.

The article Rare disease biotech Inozyme Pharma prices further upsized IPO at $16, in line with upwardly revised terms originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest IPOs Videos

Club Revenue: How CFOs Can Prepare for IPO

Jan 03, 2022

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More